NCT05059236: A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Sponsor: Bayer. Phase: PHASE2. Conditions: Metastatic Hormone-sensitive Prostate Cancer